C
Catey Bunce
Researcher at King's College London
Publications - 466
Citations - 20655
Catey Bunce is an academic researcher from King's College London. The author has contributed to research in topics: Visual acuity & Randomized controlled trial. The author has an hindex of 71, co-authored 444 publications receiving 17575 citations. Previous affiliations of Catey Bunce include UCL Institute of Ophthalmology & University College London.
Papers
More filters
Journal ArticleDOI
A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2
Michel Michaelides,Michel Michaelides,Andrew Kaines,Robin Hamilton,Samantha Fraser-Bell,Ranjan Rajendram,Ranjan Rajendram,Fahd Quhill,Christopher J. Boos,Wen Xing,Catherine A Egan,Tunde Peto,Catey Bunce,R. David Leslie,Philip G Hykin +14 more
TL;DR: The study provides evidence to support the use of bevacizumab in patients with center-involving CSME without advanced macular ischemia, and the primary end point was the difference in ETDRS best-corrected visual acuity at 12 months.
Journal ArticleDOI
Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial
David F. Garway-Heath,David P. Crabb,Catey Bunce,Gerassimos Lascaratos,Francesca Amalfitano,Nitin Anand,Augusto Azuara-Blanco,Rupert R A Bourne,David C Broadway,Ian A. Cunliffe,Jeremy P. Diamond,Scott G Fraser,Tuan A. Ho,Keith R Martin,Andrew McNaught,Anil Negi,Krishna Patel,Richard A. Russell,Richard A. Russell,Ameet Shah,Paul G. D. Spry,Katsuyoshi Suzuki,E.T. White,Richard Wormald,Wen Xing,Thierry Zeyen +25 more
TL;DR: This is the first randomised placebo-controlled trial to show preservation of the visual field with an intraocular-pressure-lowering drug in patients with open-angle glaucoma, and visual field preservation was significantly longer in the latanoprost group than in the placebo group.
Journal ArticleDOI
A comparison of the causes of blindness certifications in England and Wales in working age adults (16–64 years), 1999–2000 with 2009–2010
TL;DR: For the first time in at least five decades, diabetic retinopathy/maculopathy is no longer the leading cause of certifiable blindness among working age adults in England and Wales, having been overtaken by inherited retinal disorders.
Journal ArticleDOI
A 2-Year Prospective Randomized Controlled Trial of Intravitreal Bevacizumab or Laser Therapy (BOLT) in the Management of Diabetic Macular Edema: 24-Month Data: Report 3
Ranjan Rajendram,Samantha Fraser-Bell,Andrew Kaines,Michel Michaelides,Robin Hamilton,Simona Degli Esposti,Tunde Peto,Catherine A Egan,Catey Bunce,Richard David Leslie,Philip G Hykin +10 more
TL;DR: This study provides evidence supporting longer-term use of intravitreous bevacizumab for persistent center-involving CSME and difference in ETDRS best-corrected visual acuity (BCVA) between arms.
Journal ArticleDOI
The influence of central corneal thickness and age on intraocular pressure measured by pneumotonometry, non-contact tonometry, the Tono-Pen XL, and Goldmann applanation tonometry
PA Tonnu,T A Ho,T Newson,A El Sheikh,K Sharma,Eric A. White,Catey Bunce,David F. Garway-Heath +7 more
TL;DR: IOP measurement by all four methods is affected by CCT, with the NCT affected significantly more than the GAT, and subject age has a differential effect on the IOP measurements made by the Gat and OBF compared to the Tono-Pen.